IND/GLY also numerically reduced the risk of moderate or severe exacerbation in patients with ≥2 exacerbations in the previous year, although this trend did not reach statistical significance (HR: 0.85; 95% CI: 0.70–1.03).
← all excerpts
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
1
—
—